Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-κB and CXC chemokines

Cancer Research

Volumn 65, Issue 12, 2005, Pages 5063-5069

  Karl, Elisabeta ^a   Warner, Kristy ^a   Zeitlin, Benjamin ^a   Kaneko, Tomoatsu ^a,e   Wurtzel, Lindsey ^a   Jin, Taocong ^a   Chang, Jia ^b   Wang, Shaomeng ^b   Wang, Cun Yu ^b   Strieter, Robert M ^f   Nunez, Gabriel ^d   Polverini, Peter J ^c   Nör, Jacques E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; BL 193; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; PROTEIN BCL 2; PROTEIN INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DOWN REGULATION; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; SKIN CELL; TUMOR GROWTH; UPREGULATION;

ANIMALS; CELLS, CULTURED; CHEMOKINES, CXC; CORNEAL NEOVASCULARIZATION; ENDOTHELIAL CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-8; NEOVASCULARIZATION, PHYSIOLOGIC; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; UP-REGULATION;

EID: 20444456293     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0140     Document Type: Article

References (33)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
2. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5.
3. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;61:851-8.
4. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998;273:30336-43.
5. Nör JE, Christensen J, Mooney DJ, Polverini PJ. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 1999;154:375-84.
6. Hockenbery DM, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
7. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590-607.
8. Gross A, McDonnell J, Korsmeyer SJ. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 1999;13:1899-911.
9. Adams JM, Huang DC, Puthalakath H, et al. Control of apoptosis in hematopoietic cells by the Bcl-2 family of proteins. Cold Spring Harb Symp Quant Biol 1999;64:351-8.
10. L restrict lineage choice during hematopoietic differentiation. J Biol Chem 2003;278:25158-65.
11. Nör JE, Christensen J, Liu J, et al. Up-regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 2001;61:2183-8.
12. de Moissac D, Mustapha S, Greenberg AH, Kirshenbaum LA. Bcl-2 activates the transcription factor NFκB through the degradation of the cytoplasmic inhibitor IκBα. J Biol Chem 1999;273:23946-51.
13. Regula BCM, Ens K, Kirshenbaum LA. IKKβ is required for Bcl-2-mediated NF-κB activation in ventricular myocytes. J Biol Chem 2002;277:38676-82.
14. Ricca A, Biroccio A, Del Bufalo D, Mackay AR, Santoni A, Cippitelli M. Bcl-2 over-expression enhances NF-κB activity and induces MMP-9 transcription in human MCF7 breast-cancer cells. Int J Cancer 2000;86:188-96.
15. Chen LF, Greene WC. Shaping the nuclear action of NF-κB. Nat Rev Mol Cell Biol 2004;5:392-401.
16. Suh J, Rabson AB. NF-κB activation in human prostate cancer: important mediator or epiphenomenon? J Cell Biochem 2004;91:100-17.
17. Wang CY, Mayo MW, Baldwin AS. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996;274:784-7.
18. Stanik AK, Bezbradica JS, Park JJ, et al. NF-κ B controls cell fate specification, survival, and molecular differentiation of immunoregulatory natural T lymphocytes. J Immunol 2004;172:2265-73.
19. Strieter RM, Belperio JA, Phillips RJ, Keane M. CXC chemokines in angiogenesis of cancer. Semin Cancer Biol 2004;14:195-200.
20. Bernardini G, Ribatti D, Spinetti G, et al. Analysis of the role of chemokines in angiogenesis. J Immunol Methods 2003;273:83-101.
21. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol 1994;55:97-179.
22. Mukaida N, Mahe Y, Matsushima K. Cooperative interaction of nuclear factor-κB- and cis-regulatory enhancer binding protein-like factor binding elements in activating the interleukin-8 gene by pro-inflammatory cytokines. J Biol Chem 1990;265:21128-33.
23. Wood LD, Richmond A. Constitutive and cytokine-induced expression of the melanoma growth stimulatory activity/GROα gene requires both NF-κB and novel constitutive factors. J Biol Chem 1995;270:30619-26.
24. Enis DR, Shepherd BR, Wang Y, et al. Induction, differentiation, and remodeling of blood vessels after transplantation of Bcl-2-transduced endothelial cells. Proc Natl Acad Sci U S A 2005;102:425-30.
25. Muto A, Ruland J, McAllister-Lucas LM, et al. Protein kinase C-associated kinase (PKK) mediates Bcl10-independent NF-κB activation induced by phorbol ester. J Biol Chem 2002;277:31871-6.
26. Wang S, Yang D, Lippman ME. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol 2003;30:133-42.
27. Moore BB, Arenberg DA, Addison CL, Keane MP, Polverini PJ, Strieter RM. CXC chemokines mechanism of action in regulating tumor angiogenesis. Angiogenesis 1998;2:123-34.
28. Swaroop N, Chen F, Wang L, Dokka S, Toledo D, Rojanasakul Y. Inhibition of nuclear transcription factor-κB by specific IκB kinase peptide inhibitor. Pharm Res 2001;18:1631-3.
29. Coussens LM, Tinkle C, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000;103:481-90.
30. Rabbany SY, Heissig B, Hattori K, Rafii S. Molecular pathways regulating mobilization of marrow-derived stem cells for tissue revascularization. Trends Mol Med 2003;9:109-17.
31. Jain RK, Safabakhsh N, Sckell A, et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of VEGF. Proc Natl Acad Sci U S A 1998;95:10820-5.
32. Richmond A, Fan GH, Dhawan P, Yang J. How do chemokine/chemokine receptor activations affect tumorigenesis? Novartis Found Symp 2004;256:74-89.
33. Chao DT, Korsmeyer SJ. Bcl-2 family: regulators of cell death. Annu Rev Immunol 1998;16:395-419.